Loading…

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection

PurposeTo compare the survival benefit in the adjuvant chemoradiotherapy (CRT) group and chemotherapy (CT) group for stage III gastric or gastroesophageal junction (GEJ) cancer after D2/R0 resection. Methods and MaterialsFrom January 2011 to May 2018, 819 patients (CRT group: 215 patients, CT group:...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022-07, Vol.12, p.916937-916937
Main Authors: Shi, Jinming, Kang, Wenzhe, Tang, Yuan, Li, Ning, Jiang, Liming, Yang, Lin, Wang, Shulian, Song, Yongwen, Liu, Yueping, Fang, Hui, Lu, Ningning, Qi, Shunan, Chen, Bo, Li, Yexiong, Tian, Yantao, Jin, Jing
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PurposeTo compare the survival benefit in the adjuvant chemoradiotherapy (CRT) group and chemotherapy (CT) group for stage III gastric or gastroesophageal junction (GEJ) cancer after D2/R0 resection. Methods and MaterialsFrom January 2011 to May 2018, 819 patients (CRT group: 215 patients, CT group: 604 patients) diagnosed as pathological stage III after D2/R0 resection were retrospectively collected and the survival and recurrence patterns were analyzed. The baseline characteristics were balanced based on propensity score matching (PSM). The survival benefit was compared between two groups using Kaplan-Meier analysis and Cox regression model. ResultsThe 5-year overall survival (OS) rate in the CRT group was significantly higher than that in the CT group whether before or after the PSM. The multivariate Cox regression analysis identified the significant poor OS in patients with advanced TNM stage (P < 0.001) and patients who did not receive the adjuvant CRT (P = 0.008). For the recurrence patterns, 85 (39.5%) patients in the CRT group and 300 (49.7%) patients in the CT group were diagnosed as recurrence (P = 0.011). The regional recurrence in the CRT group was less than that in the CT group (20.5% vs. 35.1%, P = 0.028). ConclusionFor patients diagnosed as stage III gastric cancer or gastroesophageal junction cancer, the addition of adjuvant chemoradiotherapy will significantly improve the overall survival and regional control.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.916937